Form 4: Director Claude Nicaise Acquires Sarepta Therapeutics Stock

Sarepta Therapeutics Director Claude Nicaise was granted 16,875 restricted stock units as part of an equity compensation award.

Summary

• Director Claude Nicaise acquired 16,875 restricted stock units (RSUs) in Sarepta Therapeutics, Inc. (SRPT).
• Each RSU represents the right to receive one share of common stock upon vesting.
• The transaction occurred on June 4, 2026.
• Following this transaction, the director's total beneficial ownership increased to 48,407 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine regulatory disclosure regarding director compensation.

Positives

• Increased equity alignment between the director and shareholders.
• The grant reflects standard corporate governance practices for director compensation.

Negatives

• None identified.

Risks

• None identified.

Future Outlook

The RSUs will vest on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders, provided it is at least 50 weeks after the previous year's meeting.

Industry Context

StockSavvy.ai notes that director equity grants are standard practice in the biotechnology sector to ensure long-term alignment with shareholder interests and retention of board expertise.

Comparison to Industry Standards

• The grant of RSUs to non-employee directors is consistent with compensation structures at peer mid-cap biotechnology firms.
• Vesting schedules tied to annual meetings are standard industry practice for board members.

Stakeholder Impact

• Shareholders benefit from increased director equity ownership, which aligns interests with long-term company performance.

Next Steps

• Vesting of the 16,875 RSUs on the earlier of the one-year anniversary or the next annual meeting.

Key Dates

Keywords

Sarepta Therapeutics, SRPT, Form 4, Insider Trading, Director Compensation, Restricted Stock Units